Investment Rating - The investment rating for the company is maintained as "Buy" [1][5]. Core Views - The company reported revenue and net profit of 318.2 million and 25.5 million RMB for the first three quarters of 2024, representing a year-over-year change of +4.8% and -19.7% respectively. The decline in profit is attributed to increased R&D and sales promotion expenses [1]. - The core business of Blood Glucose Monitoring (BGM) is developing well, and sales of Continuous Glucose Monitoring (CGM) products are expanding in both domestic and EU markets, leading to a positive outlook for the company's performance in 2024 [1][2][3]. Summary by Sections Financial Performance - For 1-3Q24, the company achieved a gross margin of 55.2%, an increase of 2.2 percentage points year-over-year. The sales, management, and R&D expense ratios were 26.5%, 10.3%, and 8.8% respectively [4]. - The company expects to achieve revenue of 4.279 billion RMB in 2024, with a projected EPS of 0.57 RMB [6][11]. Business Segments - The BGM business showed stable growth, with expectations for continued upward momentum in 2024 due to strong demand for blood glucose monitoring among diabetes patients [2]. - The CGM products performed well in the domestic market, with sales exceeding 200 million RMB in the first three quarters of 2024. The company anticipates sales to exceed 300 million RMB in 2024 [3]. Profitability and Valuation - The company has adjusted its revenue expectations for the blood glucose monitoring system and increased its sales and R&D expense forecasts. The target price for 2025 is set at 34.30 RMB, based on a PE ratio of 48x [5][9].

Investment Rating - The report maintains a "Buy" rating for the company [2][9] Core Insights - The company reported steady revenue growth in Q3 2024, with total revenue reaching 3.182 billion RMB, a year-on-year increase of 5%. However, net profit attributable to shareholders decreased by 20% to 255 million RMB, and the non-recurring net profit fell by 32% to 231 million RMB [2] - In Q3 2024, the company achieved revenue of 1.049 billion RMB, up 2% year-on-year, but net profit dropped by 59% to 57.86 million RMB, with non-recurring net profit down 62% to 53.18 million RMB [2] - The increase in sales expense ratio to 27.3% in Q3, up 4.0 percentage points year-on-year, is attributed to increased marketing efforts for CGM products and overseas market expansion [2] - The company invested 278 million RMB in R&D in the first three quarters, a 13% increase year-on-year, with an R&D expense ratio of 8.75% [2] - The CGM product "iCan" has received regulatory approval in multiple countries, and the clinical trial for FDA registration is nearing completion, indicating potential for rapid market expansion [2] Summary by Sections Financial Performance - For the first three quarters of 2024, the company reported total revenue of 3.182 billion RMB, with a 5% increase year-on-year. The net profit attributable to shareholders was 255 million RMB, down 20% year-on-year, and the non-recurring net profit was 231 million RMB, down 32% year-on-year [2] - Q3 2024 revenue was 1.049 billion RMB, a 2% increase year-on-year, while net profit decreased by 59% to 57.86 million RMB, and non-recurring net profit fell by 62% to 53.18 million RMB [2] Operational Analysis - The sales expense ratio increased significantly to 27.3% in Q3, reflecting a 4.0 percentage point rise year-on-year, driven by enhanced marketing for CGM products and overseas market initiatives [2] - The company is focusing on maintaining growth in its core chronic disease rapid testing business while fostering rapid growth in its CGM-based product line [2] Research and Development - The company allocated 278 million RMB to R&D in the first three quarters, marking a 13% increase year-on-year, with an R&D expense ratio of 8.75% [2] - The CGMS product "三诺爱看" has received registrations in various countries, and the new generation CGM product's domestic registration application has been accepted [2] Future Outlook - The company expects net profits for 2024-2026 to be 403 million RMB, 536 million RMB, and 641 million RMB, representing year-on-year growth rates of 42%, 33%, and 20% respectively [2] - The current price corresponds to a PE ratio of 39, 30, and 25 for the years 2024, 2025, and 2026 respectively, supporting the "Buy" rating [2]

三诺生物：前三季度净利润2.55亿元 同比下降19.71% 财联社10月23日电，三诺生物发布2024年第三季 度报告，前三季度实现营业收入31.82亿元，同比增长4.83%；归属于上市公司股东的净利润2.55亿元， 同比下降19.71%。 第三季度实现营业收入10.49亿元，同比增长2.05%；归属于上市公司股东的净利润5785.67万元，同比 下降59.44%。 查看公告原文 ...

三诺生物传感股份有限公司 第五届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 三诺生物传感股份有限公司（以下简称"公司"）第五届监事会第十一次会 议于 2024 年 10 月 23 日（星期三）上午 10 时在公司会议室以现场方式召开。本 次会议的通知已于 2024 年 10 月 20 日通过书面或电子邮件方式送达全体监事。 应出席本次会议的监事 3 人，实际出席本次会议的监事 3 人，分别为欧阳柏伸先 生、陈春耕先生和黄绍波先生。本次会议由监事会主席欧阳柏伸先生召集并主持， 公司董事会秘书郑霁耘女士列席了会议。会议的召集、召开符合《公司法》及《公 司章程》、《公司监事会议事规则》的规定。 二、会议审议情况 经与会监事认真审议，本次会议以现场表决方式通过如下决议： （一）审议并通过《关于公司 2024 年第三季度报告的议案》 经审核，监事会认为：公司编制和审议《2024 年第三季度报告》的程序合法 合规，符合国家法律法规、规范性文件和中国证监会、深圳证券交易所的有关规 定，报告内容真实、准确、完整，不存在任何虚假 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2024-068 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | （一）审议并通过《关于公司 2024 年第三季度报告的议案》 经审议，公司董事会认为：公司《2024 年第三季度报告》的编制和审议程序 符合相关法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反 映了公司 2024 年第三季度的财务状况、经营成果和现金流量，不存在任何虚假 记载、误导性陈述或者重大遗漏。 三诺生物传感股份有限公司 第五届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 三诺生物传感股份有限公司（以下简称"公司"）第五届董事会第十二次会 议于 2024 年 10 月 23 日（星期三）上午 9 时在公司会议室以现场结合通讯方式 召开。本次会议的通知已于 2024 年 10 月 20 日通过书面或电子邮件方式送达全 体董事。应出席本次会议的董事 7 人，实际出席本次会议的董事 7 人，分别为李 少波先生（兼任 ...

Financial Performance - Revenue for the third quarter of 2024 was RMB 1,049,008,911.45, an increase of 2.05% year-over-year[3] - Net profit attributable to shareholders of the listed company for the third quarter of 2024 was RMB 57,856,718.51, a decrease of 59.44% year-over-year[3] - Total operating revenue for the first three quarters of 2024 reached 3,182,048,562.89 yuan, a 4.8% increase compared to the same period last year[23] - Net profit attributable to the parent company's shareholders was 255,342,147.59 yuan, a 19.7% decrease compared to the same period last year[24] - Basic earnings per share decreased by 19.3% to 0.4605 yuan compared to the same period last year[24] - Net profit attributable to the parent company's owners increased to RMB 1,100,794,523.60 from RMB 920,121,591.90 at the beginning of the period[22] Assets and Liabilities - Total assets as of September 30, 2024, were RMB 5,933,439,064.87, an increase of 0.11% compared to the end of the previous year[3] - Total assets amounted to RMB 5,933,439,064.87, with total liabilities of RMB 2,358,236,382.43 and total equity of RMB 3,575,202,682.44[22] - Accounts receivable increased to RMB 527,201,805.17 from RMB 478,219,714.39 at the beginning of the period[20] - Inventory increased to RMB 681,094,723.03 from RMB 632,445,438.98 at the beginning of the period[20] - Short-term borrowings decreased to RMB 69,544,556.74 from RMB 89,880,671.68 at the beginning of the period[21] - Long-term borrowings decreased significantly to RMB 65,312,625.00 from RMB 438,202,375.00 at the beginning of the period[22] - The company's monetary funds increased to RMB 795,422,346.70 from RMB 786,037,973.76 at the beginning of the period[20] Investments and Projects - The company's investment in the iPOCT Industrial Park Phase III project increased by 67.69% compared to the beginning of the year, reaching RMB 180,160,186.03[6] - As of September 30, 2024, the company had invested RMB 998,132,500 in fundraising projects, with interest income of RMB 22,486,500, and the funds have been fully utilized according to regulations[19] Expenses and Costs - Financial expenses decreased by 32.86% to RMB 19,164,610.70, mainly due to reduced interest accrual by the subsidiary Xinnuo Health Industry Investment Co., Ltd[7] - Credit impairment losses increased by 152.47% to RMB -22,132,977.44, primarily due to increased bad debt provisions for accounts receivable by the subsidiary Trividia Health, Inc[7] - Asset impairment losses increased by 65.58% to RMB -4,578,492.42, mainly due to inventory write-downs by subsidiaries Trividia Health, Inc. and Polymer Technology Systems, Inc[7] - Non-operating income decreased by 115.55% to RMB -39,274.11, mainly due to the refund of customer deposits by the parent company[7] - Non-operating expenses decreased by 78.56% to RMB 2,527,082.93, primarily due to reduced legal fees paid by the subsidiary Trividia Health, Inc[7] - Operating costs for the first three quarters of 2024 were 2,922,130,369.96 yuan, a 5.9% increase year-over-year[23] - R&D expenses increased by 13.5% year-over-year to 278,469,037.83 yuan[23] - Sales expenses rose by 17.6% to 842,261,617.67 yuan compared to the same period last year[23] Cash Flow - Cash received from investment recovery increased by 659.10% to RMB 265.68 million, mainly due to the recovery of structured deposits and proceeds from the disposal of equity in Chengdu Smart Technology Co., Ltd. and Zhejiang Nuotai Health Technology Co., Ltd.[8] - Cash received from investment income decreased by 37.01% to RMB 727,531.17, primarily due to cash dividends received from Zhejiang Nuotai Health Technology Co., Ltd. in the previous period[8] - Cash received from the disposal of fixed assets, intangible assets, and other long-term assets increased by 235.39% to RMB 103,749.00, mainly due to increased cash recovery from the disposal of fixed assets[8] - Total cash inflow from investment activities increased by 638.90% to RMB 267.38 million, primarily due to increased cash received from investment recovery[8] - Cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets decreased by 36.23% to RMB 166.04 million, mainly due to reduced investment by the parent company compared to the same period last year[8] - Cash paid for investments increased by 471.43% to RMB 200.00 million, primarily due to increased purchases of structured deposits and other financial products by the parent company[8] - Net cash flow from financing activities decreased by 88.39% to RMB 94.49 million, mainly due to reduced cash received from borrowings and other financing activities[8] - Net cash flow from operating activities was 403,166,205.32 yuan, a 1.6% decrease year-over-year[25] - Cash received from selling goods and providing services was 3,181,478,797.82 yuan, a 2.4% increase compared to the same period last year[25] - Cash paid for employee compensation and benefits was 827,353,070.99 yuan, a 2.4% increase year-over-year[25] - Cash outflow for the purchase of fixed assets, intangible assets, and other long-term assets decreased by 36.2% to 166,036,824.52 yuan[25] - Investment cash outflow totaled 366,036,824.52, a decrease from 295,358,036.35 in the previous period[26] - Net cash flow from investment activities was -98,660,426.17, an improvement from -259,172,080.51[26] - Cash inflow from financing activities was 94,488,083.34, significantly lower than 814,024,020.41 in the previous period[26] - Net cash flow from financing activities was -279,286,544.41, an improvement from -337,367,079.28[26] - The net increase in cash and cash equivalents was 11,330,032.80, compared to a net decrease of -184,856,894.76 in the previous period[26] - The ending balance of cash and cash equivalents was 790,996,448.57, up from 625,659,807.31[26] Shareholder and Equity Information - The company's largest shareholder, Li Shaobo, holds 25.29% of the shares, totaling 142,685,648 shares, with 107,014,236 shares under restricted sale[9] - The second-largest shareholder, Che Hongli, holds 21.94% of the shares, totaling 123,806,943 shares, all of which are unrestricted[9] - The company's actual controller changed to Li Shaobo after the termination of the "Consistent Action Agreement" with Che Hongli on January 18, 2019[10] - China Bank Co., Ltd. - Huabao CSI Medical ETF holds 11,650,902 shares, accounting for 2.06% of the total shares[11] - The company repurchased 10,420,787 shares, accounting for 1.85% of the total shares, with a total repurchase amount of RMB 253,558,050.23[12] - Li Shaobo holds 107,014,236 restricted shares, accounting for a significant portion of the company's total shares[13] - The company repurchased 3,421,500 shares, accounting for 0.61% of the total shares, with a total repurchase amount of RMB 84,972,866.00[16] - The company's repurchase account holds 10,420,787 shares, accounting for 1.85% of the total shares[16] - The company's total share capital is 564,265,375 shares[12][16] - The highest repurchase price was RMB 29.637 per share, and the lowest was RMB 13.443 per share[12] - The company's repurchase plan was completed with a total repurchase amount of RMB 253,558,051.23[16] Fundraising and Convertible Bonds - The company issued 5,000,000 convertible bonds with a total face value of RMB 500,000,000, and as of September 30, 2024, 4,984,224 bonds remain unconverted[17] - The convertible bonds have a conversion price of RMB 34.61 per share[17] - The company raised a total of RMB 502,649,986.28 through a private placement of 27,987,193 shares at RMB 17.96 per share, with a net amount of RMB 485,911,986.55 after deducting issuance costs[18] - The company issued RMB 500,000,000 in convertible bonds, with a net amount of RMB 490,033,873.32 after deducting issuance costs[18] Government Subsidies and Non-Recurring Gains - The company's government subsidies for the reporting period amounted to RMB 7,772,642.00, contributing to non-recurring gains[4]

| 证券代码：300298 | 证券简称： | 三诺生物 | 公告编号：2024-066 | | --- | --- | --- | --- | | 债券代码：123090 | 债券简称： | 三诺转债 | | 三诺生物传感股份有限公司 关于向控股子公司提供财务资助的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、财务资助情况概述 三诺生物传感股份有限公司（以下简称"公司"）分别于2024年4月24日召 开第五届董事会第十次会议、第五届监事会第九次会议，于2024年5月21日召开 2023年年度股东大会，审议并通过《关于向控股子公司提供财务资助的议案》， 为解决心诺健康资金使用需求，降低上市公司整体融资成本，在不影响公司正常 经营的前提下，同意公司以不超过5亿元人民币的自有资金向控股子公司长沙心 诺健康产业投资有限公司（以下简称"心诺健康"）提供财务资助，期限为公司 2023年年度股东大会审议通过之日起三年，并按实际使用资金以不低于同类业务 同期银行贷款利率与心诺健康结算资金使用费，上述额度在授权期限内，资金可 滚动使用，同时心诺健康其他股东李少 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2024-067 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 | 获得补助 | 发放主体 | 获得补助的 | 收到补助的 | | 补助 | 补助金额（元） | 补助依据 | 是否与公司 日常经营活 | 是否具 有可持 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 的主体 | | 原因或项目 | 时间 | | 形式 | | | | | | | | | | | | | | 动相关 | 续性 | | 三诺生物 | 国家税务总 局湖南湘江 | 软件产品增 | 2024 10 | 年 | 现金 | 16,765,873.59 | 《财政部国家税务总 局关于软件产品增值 | 是 | 是 | | | 新区税务局 | 值税退税 | 月 10 | 日 | | | 税政策的通知》（财税 | | | | | | | | | | | 【2011】100 号） | | | | | | 合计 | | | ...

编号：2024-10-01 证券代码：300298 证券简称：三诺生物 债券代码：123090 债券简称：三诺转债 三诺生物传感股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|---------------------------------------------------|------------------------------------------------------------------| | | □ 特定对象调研 | □ 分析师会议 | | 投资者关系活动 | □ 媒体采访 | □ 业绩说明会 | | 类别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | 其他（"湖南辖区 | 2024 年度投资者网上集体接待日"活动） | | 参与单位名称及 | 投资者均可登陆"全景路演"网站（ | https://ir.p5w.net ），或关注微信公众 | | 人员姓名 | 号：全景财经，或下载全景路演 | APP 互动交流 | | 时间 | 2024 年 10 月 10 日 | ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2024-065 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于2024年第三季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、三诺转债（债券代码：123090）转股期为2021年6月25日至2026年12月20 日；转股价格为人民币34.61元/股。 2、2024年第三季度，共有0张"三诺转债"完成转股（票面金额共计0元人 民币），合计转成0股"三诺生物"股票（股票代码：300298）。 3、截至2024年第三季度末，公司剩余可转债为4,984,224张，剩余可转债票 面总金额为498,422,400元人民币。 根据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司 自律监管指引第15号——可转换公司债券》的有关规定，三诺生物传感股份有限 公司（以下简称"公司"或"三诺生物"）现将2024年第三季度可转换公司债券 （以下简称"可转债"）转股及公司股 ...